

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

NCT02015013

Status	RECRUITING
Phase	Phase 2
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (20)

- ICL patients:
 - Documented history of idiopathic CD4 lymphocytopenia as defined by CD4 T cell count <300 cells/microL or $<20\%$ of total T lymphocytes on 2 occasions at least 6 weeks apart in the absence of any illness or medications accounting for CD4 lymphocytopenia. Although the protocol will primarily enroll ICL patients who are lymphopenic at the time of enrollment, up to three patients who had clear documentation of ICL in the past and are currently not lymphopenic may still be enrolled for comparative purposes.
 - Hemoglobin greater than or equal to 9 g/dL
 - Human T-lymphotropic virus Type 1 (HTLV-1) and HTLV-2 seronegative
 - Persons with documented history of ICL in whom genetic analysis revealed inherited defects that are either known or suspected to be involved in development, maturation, or homeostasis of hematopoietic cells.
- ... and 15 more (see full listing online)

Exclusion (20)

- Active uncontrolled infection at the time of enrollment
 - Current autoimmune conditions requiring systemic (oral, injection, or other parenteral) therapy
 - History of vasculitis
 - Current or history of hematologic or lymphoid malignancy (leukemia)
 - History of splenomegaly or current splenomegaly on exam or ultrasound (for ICL patients)
- ... and 15 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States